<DOC>
	<DOCNO>NCT00660374</DOCNO>
	<brief_summary>This trial conduct South America . This trial aim comparison safety efficacy insulin NPH new insulin formulation blood glucose control .</brief_summary>
	<brief_title>Safety Efficacy Insulin NPH Compared New Insulin Formulation Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Isophane insulin , beef</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Isophane Insulin , Human</mesh_term>
	<mesh_term>Insulin , Isophane</mesh_term>
	<criteria>Type 2 diabetes least 12 month Current NPH treatment least 3 month alone insulin combination OADs Body Mass Index ( BMI ) less equal 40 kg/m2 HbA1c le equal 9.5 % FPG le equal 12 mmol/L Treatment Glucagonlike peptide 1 mimetics dipeptityl peptidase IV inhibitor Treatment 1 IU/kg NPH insulin daily Known hypoglycaemia unawareness recurrent major hypoglycaemia , judge Investigator Known suspect allergy trial product relate product Receipt investigational drug within one month prior trial Any condition Investigator feel would interfere trial participation evaluation result , e.g . shiftworkers</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>